Up to 8,800 hospital admissions and hundreds of deathscould be prevented, according to first Seasonal Vulnerability Report1
Thousands of older Australians are being hospitalised as temperatures plummet across Australia, with a new report revealing a 32 per cent spike in admissions during winter compared to summer for deadly and common heart conditions.1
Novartis today announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis. The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.
This site is intended for an audience in Australia